GlaxoSmithKline Biologicals (NYSE:GSK) and AFFiRiS GmbH announced the execution of a collaboration agreement granting GSK exclusive rights to AFFiRiS’s Alzheimer’s disease vaccine programs, aimed at treating Alzheimer’s by targeting beta-amyloid.
As part of the agreement, GSK is acquiring exclusive rights to develop and commercialize two Alzheimer’s disease vaccine candidates that are based on AFFiRiS AFFiTOPE technology and are currently in Phase I clinical development. AFFiRiS is also granting GSK an exclusive option to develop and commercialize alternative Alzheimer’s disease vaccine candidates which are in pre-clinical development.
Upfront: €22.5 million ($29 million)
Milestones: €407.5 million ($523 million)
Nice chunk of change. I’m not personally a big believer in Alzheimer’s disease vaccines in general (or these APP/tau approaches) but I’ve been wrong before and I guess covering your bases for ~$29M is a fine strategy if you have the money.
Eventually though, one of these gamma secretase/APP/tau based approaches to treating or, in this case, preventing AD better show at least a shred of efficacy in clinical trials or some poor licensing professional is getting fired at pretty much every major pharma company. Sheep.